240 related articles for article (PubMed ID: 24783220)
1. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.
Nagai T; Kanasaki M; Srivastava SP; Nakamura Y; Ishigaki Y; Kitada M; Shi S; Kanasaki K; Koya D
Biomed Res Int; 2014; 2014():696475. PubMed ID: 24783220
[TBL] [Abstract][Full Text] [Related]
2. βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.
Gao R; Kanasaki K; Li J; Kitada M; Okazaki T; Koya D
FEBS Open Bio; 2019 May; 9(5):1029-1038. PubMed ID: 30972974
[TBL] [Abstract][Full Text] [Related]
3. Endothelial FGFR1 (Fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice.
Li J; Liu H; Srivastava SP; Hu Q; Gao R; Li S; Kitada M; Wu G; Koya D; Kanasaki K
Hypertension; 2020 Dec; 76(6):1935-1944. PubMed ID: 33131311
[TBL] [Abstract][Full Text] [Related]
4. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Nitta K; Shi S; Nagai T; Kanasaki M; Kitada M; Srivastava SP; Haneda M; Kanasaki K; Koya D
Biomed Res Int; 2016; 2016():9172157. PubMed ID: 27088094
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655
[TBL] [Abstract][Full Text] [Related]
6. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.
Srivastava SP; Shi S; Kanasaki M; Nagai T; Kitada M; He J; Nakamura Y; Ishigaki Y; Kanasaki K; Koya D
Sci Rep; 2016 Jul; 6():29884. PubMed ID: 27425816
[TBL] [Abstract][Full Text] [Related]
7. FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway.
Li J; Shi S; Srivastava SP; Kitada M; Nagai T; Nitta K; Kohno M; Kanasaki K; Koya D
Cell Death Dis; 2017 Aug; 8(8):e2965. PubMed ID: 28771231
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Br J Pharmacol; 2020 Aug; 177(16):3691-3711. PubMed ID: 32352559
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.
Zhang L; Xu LM; Chen YW; Ni QW; Zhou M; Qu CY; Zhang Y
World J Gastroenterol; 2012 Oct; 18(37):5283-8. PubMed ID: 23066324
[TBL] [Abstract][Full Text] [Related]
10. microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney.
Srivastava SP; Hedayat AF; Kanasaki K; Goodwin JE
Front Pharmacol; 2019; 10():904. PubMed ID: 31474862
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.
Kanasaki K
J Diabetes Investig; 2020 May; 11(3):516-526. PubMed ID: 31997585
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p.
Hu Q; Li J; Nitta K; Kitada M; Nagai T; Kanasaki K; Koya D
Biochem Biophys Res Commun; 2018 Jan; 495(3):2214-2220. PubMed ID: 29269295
[TBL] [Abstract][Full Text] [Related]
13. Protective Effects of Eicosapentaenoic Acid on the Glomerular Endothelium via Inhibition of EndMT in Diabetes.
Yasuzawa T; Nakamura T; Ueshima S; Mima A
J Diabetes Res; 2021; 2021():2182225. PubMed ID: 34977254
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
[TBL] [Abstract][Full Text] [Related]
15. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.
Kanasaki K; Nagai T; Nitta K; Kitada M; Koya D
Front Pharmacol; 2014; 5():70. PubMed ID: 24782774
[TBL] [Abstract][Full Text] [Related]
17. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.
Shi S; Srivastava SP; Kanasaki M; He J; Kitada M; Nagai T; Nitta K; Takagi S; Kanasaki K; Koya D
Kidney Int; 2015 Sep; 88(3):479-89. PubMed ID: 25830763
[TBL] [Abstract][Full Text] [Related]
18. The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.
Eriguchi M; Bernstein EA; Veiras LC; Khan Z; Cao DY; Fuchs S; McDonough AA; Toblli JE; Gonzalez-Villalobos RA; Bernstein KE; Giani JF
J Am Soc Nephrol; 2018 Oct; 29(10):2546-2561. PubMed ID: 30185469
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
20. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
Zhang Y; Zhang ZG; Chopp M; Meng Y; Zhang L; Mahmood A; Xiong Y
J Neurosurg; 2017 Mar; 126(3):782-795. PubMed ID: 28245754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
